[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"b-cell-precursor-acute-lymphoblastic-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:b-cell-precursor-acute-lymphoblastic-leukemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100574747","ngs-mrd-guided-blinatumomab-treatment-for-pediatric-b-all-100574747",false,"NCT06763302","NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL","Inclusion Criteria:\n\n* Clincial dianogsis of acute lymphoblastic leukemia (B-cell type) by morphology, immunology, cytogenetics, and molecular biology (MICM).\n* Age ≥1 year and \\\u003C18 years.\n* Informed consent signed, with the parents or guardians agreeing to a unified treatment protocol.\n\nExclusion Criteria:\n\n* Age \\\u003C1 year or ≥18 years.\n* Immunophenotyping suggests mature B-cell leukemia, mixed-lineage leukemia, or T-cell acute lymphoblastic leukemia.\n* Secondary leukemia or second tumor, CML blast phase ALL.\n* Other tumors or immunodeficiency diseases present.","ALL","1 Year","18 Years",{"count":19,"type":20},1220,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.\n\nThe main questions it aims to answer are:\n\n1. Whether the application of blinatumomab can improve the long-term survival of next generation sequence (NGS) MRD-positive B-ALL children after consolidation therapy?\n2. Whether the application of blinatumomab can benefit the NGS MRD-negative B-ALL children after consolidation therapy?",[26,27,28,29],"B Cell Precursor Acute Lymphoblastic Leukemia","Pediatric","Minimal Residual Disease","Next Generation Sequencing (NGS)","NOT_YET_RECRUITING","2025-01-02",{"date":33,"type":34},"2025-01-08","ACTUAL",{"date":36,"type":20},"2025-01-01",{"date":38,"type":20},"2030-12-31",{"name":40,"class":41},"The Children's Hospital of Zhejiang University School of Medicine","OTHER"]